WO2014132142A2 - Method of detaching adherent cells for flow cytometry - Google Patents
Method of detaching adherent cells for flow cytometry Download PDFInfo
- Publication number
- WO2014132142A2 WO2014132142A2 PCT/IB2014/001133 IB2014001133W WO2014132142A2 WO 2014132142 A2 WO2014132142 A2 WO 2014132142A2 IB 2014001133 W IB2014001133 W IB 2014001133W WO 2014132142 A2 WO2014132142 A2 WO 2014132142A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- adherent cells
- sample
- cell
- media
- Prior art date
Links
- 230000001464 adherent effect Effects 0.000 title claims abstract description 115
- 238000000034 method Methods 0.000 title claims abstract description 86
- 238000000684 flow cytometry Methods 0.000 title claims abstract description 85
- 238000005406 washing Methods 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 512
- 230000006907 apoptotic process Effects 0.000 claims description 49
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- 239000002738 chelating agent Substances 0.000 claims description 12
- 230000004900 autophagic degradation Effects 0.000 claims description 9
- 229910021645 metal ion Inorganic materials 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 238000007747 plating Methods 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000003556 assay Methods 0.000 abstract description 15
- 230000006727 cell loss Effects 0.000 abstract description 6
- 238000007790 scraping Methods 0.000 abstract description 4
- 230000002779 inactivation Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 37
- 239000000523 sample Substances 0.000 description 36
- 239000000975 dye Substances 0.000 description 29
- 230000001640 apoptogenic effect Effects 0.000 description 22
- 239000003642 reactive oxygen metabolite Substances 0.000 description 21
- 230000004987 nonapoptotic effect Effects 0.000 description 19
- 239000013641 positive control Substances 0.000 description 19
- 238000013537 high throughput screening Methods 0.000 description 14
- 238000000926 separation method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 9
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000002572 peristaltic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 210000004957 autophagosome Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- MLEBFEHOJICQQS-UHFFFAOYSA-N monodansylcadaverine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCCCCN MLEBFEHOJICQQS-UHFFFAOYSA-N 0.000 description 4
- VCMMXZQDRFWYSE-UHFFFAOYSA-N plumbagin Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1O VCMMXZQDRFWYSE-UHFFFAOYSA-N 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- 102100030497 Cytochrome c Human genes 0.000 description 3
- 108010075031 Cytochromes c Proteins 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 231100000991 Reactive Oxygen Species (ROS) Photosafety Assay Toxicity 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000149 argon plasma sintering Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- ZMOIGGHUSNHCAB-UHFFFAOYSA-N Isoplumbagin Natural products C1=CC(O)=C2C(=O)C(C)=CC(=O)C2=C1 ZMOIGGHUSNHCAB-UHFFFAOYSA-N 0.000 description 2
- 101710149632 Pectinesterase A Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ALPCEXCHMFUSAN-UHFFFAOYSA-N beta-Dihydroplumbagin Natural products C1=CC=C2C(=O)C(C)CC(=O)C2=C1O ALPCEXCHMFUSAN-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DWIOTGOAYNMNOI-HWKANZROSA-N (6-methyl-5,8-dioxonaphthalen-1-yl) (e)-but-2-enoate Chemical compound O=C1C(C)=CC(=O)C2=C1C=CC=C2OC(=O)/C=C/C DWIOTGOAYNMNOI-HWKANZROSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 1
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000007755 F10 Nutrient Mixture Substances 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000007756 Ham's F12 Nutrient Mixture Substances 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004961 autolysosome Anatomy 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 238000011090 industrial biotechnology method and process Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- JZRYQZJSTWVBBD-UHFFFAOYSA-N pentaporphyrin i Chemical compound N1C(C=C2NC(=CC3=NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JZRYQZJSTWVBBD-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- G01N15/01—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2510/00—Detection of programmed cell death, i.e. apoptosis
Definitions
- This description relates to a method of detaching adherent cells for flow cytometry.
- Flow cytometry can provide a powerful and accurate measure of cellular information down to the single cell and can be used to measure apoptosis in cells.
- flow cytometry requires cells to be in suspension as they pass through tubing leading cells through the various lasers and detectors. This in itself can be one of the limitations of flow cytometry, as test experiments have to be in suspension. For this reason suspension cell lines can be preferred, as they provide a platform immediately compatible with high throughput flow cytometry.
- Adherent cells can be cultured in suitable numbers and trypsinized to obtain a cell suspension suitable for use in flow cytometry. Working with adherent cells can, thus, limit the potential for high throughput flow cytometry assays because downstream processing including washing and trypsinisation can result in cell loss even before reaching the flow cytometer.
- a method for detaching adherent cells can include adding a cell lifting solution to a media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution.
- the sample of adherent cells can include HeLa cells, DU145 cells, HT1080 cells, BT20 cells, MCF-7 cells or BJ fibroblasts.
- the sample of adherent cells can be incubated with the cell lifting solution for five minutes or more.
- the sample of adherent cells can be incubated with the cell lifting solution for fifteen minutes or more.
- the sample of adherent cells can be incubated with the cell lifting solution for thirty minutes or more.
- the cell lifting solution can include a metal ion chelator.
- the metal ion chelator can be EDTA.
- the cell lifting solution can be free of enzyme.
- a method for detaching adherent cells for flow cytometry can include adding a cell lifting solution to a media including a sample of adherent cells, incubating the sample of adherent cells with the cell lifting solution, and analyzing the sample of adherent cells by flow cytometry.
- the method can further comprise adding an indicator of apoptosis to the sample of adherent cells.
- the indicator of apoptosis can be a dye, a fluorophore or an antibody.
- the method can further comprise adding a stimulus to the media.
- the stimulus can be a drug or extract.
- the adherent cells are not washed with a washing solution between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry.
- the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be four hours or less.
- the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be three hours or less.
- the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be two hours or less.
- the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be one hour or less.
- the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be 30 minutes or less, for example, 15-30 minutes.
- the stimulus can be added to the media prior to adding the cell lifting solution to the media.
- the cell lifting solution can include a metal ion chelator.
- the metal ion chelator can be EDTA.
- the pH of the cell lifting solution can be betweek 6.1 and 6.4.
- the cells are not washed using centrifugation after lifting. The cells can be stained with a dye/stain and and subjected to flow cytometry.
- a method of collecting adherent cells can include plating a first sample of adherent cells in media on a cell culture plate; plating a second sample of adherent cells in media on a cell culture plate, wherein the second sample of adherent cells includes a second number of adherent cells; adding a control buffer to the media of the first sample of adherent cells; adding a stimulus to the media of the second sample of adherent cells; adding cell lifting solution to the media of the first sample of adherent cells and to the media of the second sample of adherent cells, wherein the first sample includes a first number of adherent cells at the time the cell lifting solution is added to the media and the second sample includes a second number of adherent cells at the time the cell lifting solution is added to the media; incubating the first and second samples of adherent cells, thereby detaching the first and second samples of adherent cells from the cell plate; collecting the first sample of adherent cells, wherein the number of adherent cells collected from the
- FIG. 1 is a flow diagram outlining a method for detaching adherent cells for flow cytometry.
- FIG. 2A is a graph showing the separation of untreated and treated BJ cells using flow cytometer following the performance of a cell detachment method.
- FIG. 2B is a ID histogram of untreated and treated BJ cells following the performance of a cell detachment method.
- FIG. 2C is a bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated population of BJ cells following the performance of a cell detachment method.
- FIG. 3A is a graph showing the separation of untreated and treated MCF-7 cells following the performance of a cell detachment method.
- FIG. 3B is a ID histogram of untreated and treated MCF-7 cells following the performance of a cell detachment method.
- FIG. 3C is a bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated population of MCF-7 cells following the performance of a cell detachment method.
- FIG. 4A is a graph showing the separation of untreated and treated HeLa cells following the performance of a cell detachment method.
- FIG. 4B is a ID histogram of untreated and treated HeLa cells following the performance of a cell detachment method.
- FIG. 4C is a bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated population of HeLa cells following the performance of a cell detachment method.
- FIG. 5A shows separation of untreated (blue) and treated (red) cells based on FL2-H and SSC-H profile
- FIG. 5B shows ID Histogram of untreated (blue) and treated (red) cells measuring fluorescence in the FL2-H channel and applying gates to delineate Non-apoptotic (blue) and Apoptotic (red) cells
- FIG. 5C is bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated (positive control) population of cells.
- FIG. 6 shows ID Histogram of untreated (blue) and treated (red) cells measuring fluorescence in the PE-A channel and applying gates to delineate Non- apoptotic (blue) and Apoptotic (red) cells as measured using BD LSRFortessa HTS flow cytometer.
- FIG. 7A shows separation of unstained (blue), untreated (red) and treated (green) cells based on FL2-H and FL-l-H profile (A);
- FIG. 7B shows ID Histogram of unstained (blue), untreated (red) and treated (green) cells measuring fluorescence in the FL2-H channel (B) as measured using BD LSRFortessa HTS flow cytometer.
- FIG. 8 shows untreated (red) and treated cells for MMP disruption in DU145 cells as measured using BD LSRFortessa HTS flow cytometer.
- Some of these indicative features of apoptosis can act as markers to determine the state of apoptosis in a population of cells.
- Flow cytometry is a process by which cells in suspension can be flowed through a fluid handling device and characterized and separated by microfluidic processes according to their light scattering properties.
- cells can be individually passed through a laser in a stream of isotonic saline, for example. Detection of the light scattering properties can allow a computer to characterize each cell according to its size and structure. In a heterogeneous population of cells, the proportion of each type of cell can be determined, and it can even be possible through rapid gating to separate distinct populations into individual receptacles in the course of an analysis.
- cells can be labeled with fluorescent antibodies, allowing a flow cytometer to detect protein expression levels within cells.
- flow cytometry is a technique that can provide a powerful and accurate measure of cellular information down to the single cell and is widely used to measure apoptosis in the cells.
- Flow cytometry can use a machine built on the principal of detecting signals/information by employing lasers to excite fluorophores and detectors to acquire emissions given off by flours.
- Flow cytometry can require cells to be in suspension as they pass through tubing, leading the cells through various lasers and detectors. For this reason, suspension cell lines can be preferred as they provide a platform immediately compatible with high throughput flow cytometry. (Black CB, et al. Cell-based screening using high-throughput flow cytometry. Assay Drug Dev
- Protocols described herein overcome these disadvantages.
- the methods are advantageous because adherent cells can now be used for medium to high throughput flow cytometry, for example in 96 well plate scale.
- Flow cytometers are able to analyze several thousand cells every second, in "real time,” and can actively separate and isolate cells having specified properties.
- a flow cytometer is similar to a microscope, except that, instead of producing an image of the cell, flow cytometry offers "high-throughput" (for a large number of cells) automated quantification of set parameters.
- Adherent cells can be prepared for high throughput flow cytometry. Samples can be measured at a rate of up to 40 wells per minute.
- cells, such as BJ cells can be seeded at a density of 5x10 cells per well with 96 well plates.
- the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be four hours or less, three hours or less, two hours or less, or one hour or less.
- the method here minimizes cells' time out of media, which lowers the baseline of apoptotic cells.
- the method here also minimizes cell trauma as neither scraping is required to lift cells nor harsh lifting solutions like trypsin are used.
- the method here can achieve effective separation.
- the percent of cells separated to single cells can be 75% or more, 80% or more, 85% or more, 90% or more, or 95% or more [0042] EXAMPLES
- the cells were shaken at 750 rpm with an Orbital shaker for 20 seconds and allowed to settle for 16-24 hrs in 5% C0 2 incubator at 37°C.
- a desired concentration of drug was added to cells in a volume of 5 ⁇ 1 to make the final volume per well up to 50 ⁇ .
- the cells and drug were mixed at 750 rpm with an Orbital shaker for 20 seconds and incubated again for desired period of time. Twelve microliters of 15mM EDTA pH 6.14 (upto 20mM can be added depending on the cell line) were added per well, mixed at 750 rpm with an Orbital shaker for 20 seconds and incubated at 37°C for 45 min to 1 hour (until cells lift).
- the cells were analyzed on flow cytometer setting a threshold for FSC-H of 80,000, cytometer speed at medium (2 ⁇ 1/8 ⁇ ), peristaltic pump speed at 23 rpm, shaking on 1800 rpm, gating on 2D plot of FSC vs SSC and a ID plot measuring FL2-H/FL3-H on the X axis.
- the HTFC system was used.
- FIGS. 2, 3 and 4 showsthe results obtained using three different cell lines BJ, MCF-7 and HeLa, respectively, using the protocol shown in FIG. 1.
- the apoptotic cells were stained with the APOPercentage dye due to flipping of cell membrane, whereas non- apoptotic cells could not take up this dye due to a normal cell membrane.
- BJ fibroblast cells were analyzed by flow cytometry on an Accuri C6 flow cytometer to determine the percentage of cells undergoing apoptosis (FIG. 2).
- Cells were seeded at a density of 5x10 cells per well in 96 well plate.
- Cells exposed to 2.5mM H 2 0 2 for 30 minutes or 62 ⁇ EDTA pH 6.14 for 15-30 min. added to cells after removing media were used as a positive control for apoptosis.
- Cells were lifted and stained with ⁇ APOPercentage dye. The cells were then analyzed by flow cytometry. As shown in FIG. 2A, untreated and treated cells were separated based on FL2-H and SSC-H profile.
- FIG. 2A untreated and treated cells were separated based on FL2-H and SSC-H profile.
- Untreated and treated HeLa cells were also analyzed by flow cytometry on an Accuri C6 flow cytometer to determine the percentage of cells undergoing apoptosis (FIG. 4).
- Cells were seeded at a density of 5x10 cells per well in 96 well plate.
- Cells treated with 2.5mM H 2 0 2 for 30 minutes or 62 ⁇ EDTA pH 6.14 for 15-30 min. added to cells after removing media wereused as a positive control for apoptosis.
- Cells were lifted and stained with ⁇ APOPercentage dye. The cells were then analyzed by flow cytometry. Separation of untreated and treated cells based on FL2-H and SSC-H profile is shown in FIG. 4A.
- FIG. 4A FIG.
- Cancer cells have the ability to avoid apoptosis, which thus presents an interesting event to quantify when determining the ability of drugs to induce apoptosis.
- APOPercentage protocol with results is described for five cell lines (HeLa (Cervical cancer), MCF-7 (Breast Cancer), DU145 (Prostate Cancer), HT1080 (Colon Cancer), and BJ (Normal Fibroblasts). Apoptotic cells take up APOPercentage dye when membrane movement occurs and phosphatidylserine is exposed to the outer leaflet.
- FIGS. 5A-C and Table 1 show results of APOPercentage assay in 96-well plate on Accuri C6 HTFC System ( Intellicyt).
- FIGS. 5A-C show that HeLa Cells untreated (blue) or treated (red) were analyzed by flow cytometry on an Accuri C6 flow cytometer to determine the percentage of cells undergoing apoptosis.
- Cells were seeded at a density of 5x10 cells per well in a 96-well plate. Following day, cells were treated with 2.5 mM ⁇ 2 0 2 for 30 min. or 62 ⁇ EDTA pH 6.14 for 15-30 min. added to cells after removing media as a positive control for apoptosis for 15-30 min. Cells were lifted with EDTA and stained with ⁇
- FIG. 5A Separation of untreated (blue) and treated (red) cells based on FL2-H and SSC-H profile (FIG. 5A). ID Histogram of untreated (blue) and treated (red) cells measuring fluorescence in the FL2-H channel and applying gates to delineate Non-apoptotic (blue) and Apoptotic (red) cells (FIG. 5B). Bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated (positive control) population of cells (FIG. 5C).
- Table 1 shows different aspects of method standardized using various cell lines. 'Stability of cells in EDTA' refers to the time limit until the percentage of stained cells remain ⁇ 10% in negative control.
- FIG. 6 and Table 2 show results of APOPercentage assay in 96-well plate on BD LSRFortessa HTS (BD Biosciences).
- MMP is a reflection of the permeability of the mitochondria membrane as it consists of an outer and inner membrane, which maintains a gradient of H+ ions at the inner membrane space. These H+ ions are used in the production of ATP, which serves as an energy source required for enzymatic reactions to take place and to balance energy homeostasis within the cell.
- ATP serves as an energy source required for enzymatic reactions to take place and to balance energy homeostasis within the cell.
- Cells undergoing apoptosis often experience a decrease in ATP supply as a result of MMP disruption.
- disruption of MMP leads to the release of proapoptotic factors, such as cytochrome c, from the mitochondria into the cytosol, thus driving cells towards apoptosis.
- JC-1 is a membrane permeable dye with interesting fluorescence spectrum depending on the state of the dye.
- MMP is not disrupted and JC-1 accumulates in the mitochondria as it is attracted to the high electrochemical-gradient maintained within the inner membrane.
- JC-1 forms J aggregates, which have a fluorescence emission at 580-590 nm thus fluorescing red.
- JC-1 cannot aggregate due to loss of the gradient within the mitochondria and therefore remains in a monomeric state resulting in a fluorescence emission of 530 nm (green fluorescence).
- FIG. 8 and Table 4 show MMP assay in 96-well plate on BD LSRFortessa
- DU145 and MCF-7 Cells were analyzed by flow cytometry on a BD LSRFortessa HTS to determine the level of MMP in cells. Data was analyzed using
- H2O2 as a positive control (blue) for MMP disruption.
- DU145 cells were stained with a final concentration of 2 ⁇ JC-l dye (representative image). Cells were lifted with
- MMP can be measured in adherent cells in 384-well plate format.
- 3000 cells per well were plated in 15 ⁇ of media in 384-well plate, centrifuged at 1000 rpm for 30 seconds, and shaken at 1500 rpm with an Orbital shaker for 20 seconds and allowed to settle 16-24 hours (h). Desired concentration of drug was added to cells in a volume of 3 ⁇ to make the final volume per well up to 20 ⁇ . Incubate with drug for desired period of time. Centrifuge at 1000 rpm for 30 seconds and shake at 2000 rpm with an Orbital shaker for 20 seconds. Stain cells by adding 2 ⁇ of JC- 1 to a final concentration of 2 ⁇ in a final volume of 20 ⁇ .
- ROS Reactive oxygen species
- O 2- oxygen species with an extra electron charge
- OH oxidative phosphorylation
- a balance of these species is required in the cell as excessive ROS can cause adverse effects and can lead to diseases like cancer, atherosclerosis and certain neurodegenerative diseases.
- ROS is kept in check by antioxidants like Glutathione peroxidase, catalase and superoxide dismutase (SOD), which serve to protect against ROS stress. Excessive ROS production can lead to protein unfolding, disruption of enzyme activity and also DNA damage as the available electrons in ROS can
- DCFDA 2', 7' -dichlorofluorescein diacetate
- DCF is stable and highly fluorescent and can be measured by flow cytometry with excitation of 495 nm and emission of 530 nm.
- ROS Reactive Oxygen Species
- FIGS. 9A-B and Table 5 show results of ROS assay in 96-well plate on Accuri C6 HTFC System ( Intellicyt).
- FIG. 9 HeLa and MCF-7 Cells were analyzed by flow cytometry on an Accuri C6 to determine the level of ROS in cells. Cells were seeded at a density of 5x10 cells per well in a 96-well plate, the following day cells were treated with 10 mM H 2 0 2 as a positive control for ROS and test compounds. HeLa cells were stained with a final concentration of 10 ⁇ DCFDA dye immediately after adding H202 (A). After incubation cells were lifted with EDTA and analyzed by flow cytometry.
- FIGS. 10A-B and Table 6 show results of ROS assay in 96-well plate on BD LSRFortessa HTS (BD Biosciences)
- Table 6 represents median of the peaks of ROS generation in untreated (-ve) and treated (+ve) cells for three different cell lines.
- ROS can be measured in adherent cells in 384- well plate format. The following can be the steps. Plate 3000 cells per well in 15 ⁇ of media in 384-well plate. Centrifuge at 1000 rpm for 30 seconds and shake at 1500 rpm with an Orbital shaker for 20 seconds and allow cells to settle 16-24 hours (h). Add desired concentration of drug to cells in a volume of 3 ⁇ to make the final volume per well up to 20 ⁇ . Incubate with drug for desired period of time. Centrifuge at 1000 rpm for 30 seconds and shake at 2000 rpm with an Orbital shaker for 20 seconds. Stain cells by adding 2 ⁇ of DCFDA to a final concentration of 10 in a final volume of 20 ⁇ .
Abstract
In one aspect, a method for detaching adherent cells can include adding a cell lifting solution to the media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution. No scraping or pipetting is needed to facilitate cell detachment. The method do not require inactivation of cell lifting solution and no washing of detaching cells is required to remove cell lifting solution. Detached cells can be stained with dye in the presence of cell lifting solution and are further analyzed using flow cytometer. The method has been tested using 6 different cell lines, 4 different assays, two different plate formats (96 and 384 well plates) and two different flow cytometry instruments. The method is simple to perform, less time consuming, with no cell loss and makes highthroughput flow cytometry on adherent cells a reality.
Description
METHOD OF DETACHING ADHERENT CELLS FOR FLOW CYTOMETRY
PRIORITY CLAIM
[0001] This application claims priority to U.S. Provisional Application No.
61/758,527, filed January 30, 2013, which is incorporated by reference in its entirety.
TECHNICAL FIELD
[0002] This description relates to a method of detaching adherent cells for flow cytometry.
BACKGROUND
[0003] Flow cytometry can provide a powerful and accurate measure of cellular information down to the single cell and can be used to measure apoptosis in cells.
Generally, flow cytometry requires cells to be in suspension as they pass through tubing leading cells through the various lasers and detectors. This in itself can be one of the limitations of flow cytometry, as test experiments have to be in suspension. For this reason suspension cell lines can be preferred, as they provide a platform immediately compatible with high throughput flow cytometry. Adherent cells can be cultured in suitable numbers and trypsinized to obtain a cell suspension suitable for use in flow cytometry. Working with adherent cells can, thus, limit the potential for high throughput flow cytometry assays because downstream processing including washing and trypsinisation can result in cell loss even before reaching the flow cytometer.
SUMMARY
[0004] In one aspect, a method for detaching adherent cells can include adding a cell lifting solution to a media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution.
[0005] In certain embodiments, the sample of adherent cells can include HeLa cells, DU145 cells, HT1080 cells, BT20 cells, MCF-7 cells or BJ fibroblasts. The sample of adherent cells can be incubated with the cell lifting solution for five minutes or more. The sample of adherent cells can be incubated with the cell lifting solution for fifteen minutes or more. The sample of adherent cells can be incubated with the cell lifting solution for thirty minutes or more.
[0006] In certain embodiments, the cell lifting solution can include a metal ion chelator. The metal ion chelator can be EDTA. The cell lifting solution can be free of enzyme.
[0007] In another aspect, a method for detaching adherent cells for flow cytometry can include adding a cell lifting solution to a media including a sample of adherent cells, incubating the sample of adherent cells with the cell lifting solution, and analyzing the sample of adherent cells by flow cytometry.
[0008] In certain embodiments, the method can further comprise adding an indicator of apoptosis to the sample of adherent cells. [0009] In certain embodiments, the indicator of apoptosis can be a dye, a fluorophore or an antibody.
[0010] In certain embodiments, the method can further comprise adding a stimulus to the media. The stimulus can be a drug or extract.
[0011] In certain embodiments, the adherent cells are not washed with a washing solution between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry.
[0012] In certain embodiments, the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be four hours or less. The time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be three hours or less. The time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be two hours or less. The time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be one hour or less. The time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be 30 minutes or less, for example, 15-30 minutes.
[0013] In certain embodiments, the stimulus can be added to the media prior to adding the cell lifting solution to the media.
[0014] In certain embodiments, the cell lifting solution can include a metal ion chelator. The metal ion chelator can be EDTA. The pH of the cell lifting solution can be betweek 6.1 and 6.4.
[0015] In certain embodiments, the cells are not washed using centrifugation after lifting. The cells can be stained with a dye/stain and and subjected to flow cytometry.
[0016] In another aspect, a method of collecting adherent cells can include plating a first sample of adherent cells in media on a cell culture plate; plating a second sample of adherent cells in media on a cell culture plate, wherein the second sample of adherent cells includes a second number of adherent cells; adding a control buffer to the media of the first sample of adherent cells; adding a stimulus to the media of the second sample of adherent cells; adding cell lifting solution to the media of the first sample of adherent cells and to the media of the second sample of adherent cells, wherein the first sample includes a first number of adherent cells at the time the cell lifting solution is added to the media and the second sample includes a second number of adherent cells at the time the cell lifting solution is added to the media; incubating the first and second samples of adherent cells, thereby detaching the first and second samples of adherent cells from the cell plate; collecting the first sample of adherent cells, wherein the number of adherent cells collected from the first sample is equal to 75% or more of the number of adherent cells in the first sample when the cell lifting solution was added; and collecting the second sample of adherent cells, wherein the number of adherent cells collected from the second sample is equal to 75% or more of the number of adherent cells in the second sample when the cell lifting solution was added. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 is a flow diagram outlining a method for detaching adherent cells for flow cytometry.
[0018] FIG. 2A is a graph showing the separation of untreated and treated BJ cells using flow cytometer following the performance of a cell detachment method. [0019] FIG. 2B is a ID histogram of untreated and treated BJ cells following the performance of a cell detachment method.
[0020] FIG. 2C is a bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated population of BJ cells following the performance of a cell detachment method. [0021] FIG. 3A is a graph showing the separation of untreated and treated MCF-7 cells following the performance of a cell detachment method.
[0022] FIG. 3B is a ID histogram of untreated and treated MCF-7 cells following the performance of a cell detachment method.
[0023] FIG. 3C is a bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated population of MCF-7 cells following the performance of a cell detachment method.
[0024] FIG. 4A is a graph showing the separation of untreated and treated HeLa cells following the performance of a cell detachment method.
[0025] FIG. 4B is a ID histogram of untreated and treated HeLa cells following the performance of a cell detachment method. [0026] FIG. 4C is a bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated population of HeLa cells following the performance of a cell detachment method.
[0027] FIG. 5A shows separation of untreated (blue) and treated (red) cells based on FL2-H and SSC-H profile; FIG. 5B shows ID Histogram of untreated (blue) and treated (red) cells measuring fluorescence in the FL2-H channel and applying gates to delineate Non-apoptotic (blue) and Apoptotic (red) cells; FIG. 5C is bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated (positive control) population of cells.
[0028] FIG. 6 shows ID Histogram of untreated (blue) and treated (red) cells measuring fluorescence in the PE-A channel and applying gates to delineate Non- apoptotic (blue) and Apoptotic (red) cells as measured using BD LSRFortessa HTS flow cytometer.
[0029] FIG. 7A shows separation of unstained (blue), untreated (red) and treated (green) cells based on FL2-H and FL-l-H profile (A); FIG. 7B shows ID Histogram of unstained (blue), untreated (red) and treated (green) cells measuring fluorescence in the FL2-H channel (B) as measured using BD LSRFortessa HTS flow cytometer.
[0030] FIG. 8 shows untreated (red) and treated cells for MMP disruption in DU145 cells as measured using BD LSRFortessa HTS flow cytometer.
[0031] FIGS. 9A-B shows analysis of HeLa and MCF-7 cells by flow cytometry on an Accuri C6 to determine the level of ROS in cells.
[0032] FIGS. 10A-B shows untreated (blue peak) and treated cells (red peak) for ROS as measured using BD LSRFortessa HTS flow cytometer.
[0033] FIG. 11A shows the percentages of cells after various wash steps for DU145 cells, and FIG. 11B) shows results for HeLa cells. This data compares the retained cell number in conventionally used method as compared to our method.
DETAILED DESCRIPTION
[0034] Apoptosis is a form of programmed cell death that plays an important role in normal homeostasis of dividing cells and their development. Apoptosis also can play a role in diseases, such as cancer. Cancer cells have the ability to avoid apoptosis which thus presents an interesting event to quantify when determining the ability of drugs to induce apoptosis in cancer cells. Features of apoptosis can include phosphatidyl serine exposure, activation of endonucleases leading to DNA fragmentation, nuclear
condensation, blebbing and mitochondrial changes resulting in loss of mitochondrial membrane potential and release of cytochrome c. (Denecker G, et al. Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in
mitochondrial transmembrane potential. FEBS Lett, 2000, 465:47-52; Yivgi-Ohana N, et al. Utilizing mitochondrial events as biomarkers for imaging apoptosis. Cell Death Dis, 2011, 2:el66; Bertho AL, et al. Flow cytometry in the study of cell death. Mem Inst Oswaldo Cruz, 2000, 95:429-433; Wlodkowic D, et al. Cytometry of apoptosis.
Historical perspective and new advances. Exp Oncol, 2012, 34:255-262, each of which is incorporated by reference in its entirety.) Some of these indicative features of apoptosis can act as markers to determine the state of apoptosis in a population of cells.
[0035] Flow cytometry is a process by which cells in suspension can be flowed through a fluid handling device and characterized and separated by microfluidic processes according to their light scattering properties. In this technique, cells can be individually passed through a laser in a stream of isotonic saline, for example. Detection of the light scattering properties can allow a computer to characterize each cell according to its size and structure. In a heterogeneous population of cells, the proportion of each type of cell can be determined, and it can even be possible through rapid gating to separate distinct populations into individual receptacles in the course of an analysis. In addition to straightforward light scattering properties, cells can be labeled with fluorescent antibodies, allowing a flow cytometer to detect protein expression levels within cells.
Multiple antibodies can be used. In extreme cases, flow cytometry can have the capability to measure 18 fluorescent colors in a single analysis. The data collected can be displayed on an X/Y axis histogram. For example, size can be charted versus structural complexity; in the case of fluorescence data collection, green-labeled protein expression can be charted against another protein that is labeled with a red label/marker, allowing discernment of relationships between protein pathways according to the cell's
environmental conditions.
[0036] Because of the nature of the technique, in which cells are free-floating in solution as they pass through the laser, flow cytometry was originally applied to cells that only grew in suspension such as blood-derived cell types. However, this technique has now been applied to adherent cells as well. The technique obviously requires lifting adherent cells from their substrate so they can be carried in fluid through the laser.
Considerable debate revolves around whether the act of removing cells from their natural substrate can introduce artifacts into cell data collection. [0037] Flow cytometry has been used mostly as a basic research tool and has been regarded as a labor intensive procedure, for which the data sets gathered can be cumbersome to process. In many labs, it has been traditional to manually feed a cell suspension in a test tube to a "sipper" that draws each sample into the flow cytometry machine. A lack of sample standardization, a taxing sample preparation method, and the generation of large amounts of data meant flow cytometry was more suited to preparing basic research papers than industrial biotechnology applications. Recently, however, improvements in data management and adaptation of flow cytometry apparatuses to robotically collected and analyzed cells from 96- and 384- well microplates has allowed flow cytometry to be used for large pharma-scale research. Flow cytometry can have enormous potential in this regard; the capability to simultaneously measure two to ten different protein expression patterns, as well as basic cell phenotype, makes flow cytometry ideal for characterizing cellular response to changing environmental conditions such as exposure to therapeutic candidates in a drug screening campaign.
[0038] Many drug discovery campaigns focus on apoptosis, as activation of this cell death pathway is seen as a key outcome for anti-cancer therapeutics. A hallmark feature of adherent cells can be their natural tendency to detach from their substrate as apoptosis progresses. Flow cytometry can rely on standard immunofluorescence protocols, in which the growth medium can be removed from a layer of cells, a fluorescently tagged antibody
can be added to the cells, and then several washes can be applied to remove unbound antibody. In a protocol involving apoptosis detection, a prominent concern can be that medium aspiration and subsequent washes can remove detached and loosely adhered apoptotic cells, a potentially essential cell population to characterize in any screening campaign seeking to assess cytotoxicity.
[0039] In other words, flow cytometry is a technique that can provide a powerful and accurate measure of cellular information down to the single cell and is widely used to measure apoptosis in the cells. Flow cytometry can use a machine built on the principal of detecting signals/information by employing lasers to excite fluorophores and detectors to acquire emissions given off by flours. Flow cytometry can require cells to be in suspension as they pass through tubing, leading the cells through various lasers and detectors. For this reason, suspension cell lines can be preferred as they provide a platform immediately compatible with high throughput flow cytometry. (Black CB, et al. Cell-based screening using high-throughput flow cytometry. Assay Drug Dev
Technol, 2011, 9:13-20, which is incorporated by reference in its entirety). Adherent cells can be cultured in required numbers and can be trypsinized to obtain a cell suspension suitable for use in flow cytometry. Routinely used protocols include various wash and centrifugation steps that make protocols cumbersome and time consuming. Working with adherent cells can, thus, limit the potential for high throughput flow cytometry assays, because downstream processing, including washing and trypsinisation, can result in cell loss even before reaching the flow cytometer.
[0040] Accordingly, it would be advantageous to develop a protocol that allows the lifting of adherent cells without removing media and eliminate wash steps. Protocols described herein overcome these disadvantages. The methods are advantageous because adherent cells can now be used for medium to high throughput flow cytometry, for example in 96 well plate scale.
Adherent cells refers to cells, cell lines, and cell systems, whether prokaryotic or eukaryotic, that remain associated with, immobilized on, or otherwise in contact with the surface of a substrate, and remain so through washing or medium exchange procedures. Examples of cells that can be grown as adherent cells or immobilized on a surface are liver or liver-derived cells including primary hepatocytes and liver epithelial cells, epithelial cells in general, endothelial cells in general, neuronal cells, mesenchymal cells, pancreatic cells, skeletal muscle cells, cardiomyocytes, carcinoma-derived cells, bone
marrow cells, islets of Langerhans, adrenal medulla cells, osteoblasts, osteoclasts, T- lymphocytes, neurons, glial cells, ganglion cells, retinal cells, and myoblast cells. Stem cells can also be used; examples are mesenchymal stem cells, neuronal stem cells, induced pluripotent stem cells, hematopoietic stem cells, mouse embryonic stem cells, and human embryonic stem cells. Specific examples of adherent cells include HeLa
(cervical carcinoma), HT1080 (Colon carcinoma), DU145 (Prostate cancer), MCF-7 and BT20 (Breast cancer) and BJ (normal fibroblasts). The sample of adherent cells can be incubated with the cell lifting solution for five minutes or more, fifteen minutes or more, thirty minutes or more, or one hour or more.
[0022] A growth medium or culture medium is a liquid or gel designed to support the growth of microorganisms or cells. There are two major types of growth media: those used for cell culture, which use specific cell types derived from plants or animals, and microbiological culture, which are used for growing microorganisms, such as bacteria or yeast. The most common growth media for microorganisms are nutrient broths and agar plates; specialized media are sometimes required for microorganism and cell culture growth. Some organisms, termed fastidious organisms, require specialized environments due to complex nutritional requirements. Viruses, for example, are obligate intracellular parasites and require a growth medium containing living cells. There are different types of media for growing different types of cells. Media that can be used to grow cells include Dulbecco' s Modified Eagle Medium, Minimum Essential Media, RPMI Medium 1640, Iscove's Modified Dulbecco's Medium, F10 Nutrient Mixture, Ham's F12 Nutrient Mixture, and so on. Additionally, the media can include salts, amino acids, Fetal bovine serum, or Fetal Calf Serum.
[0023] A cell lifting solution can be used to dissociate adherent cells. The cell lifting solution can be free of enzyme and can contain a chelator or a mixture of chelators. A chelator is a chemical compound in the form of a heterocyclic ring, containing a metal ion attached by coordinate bonds to at least two nonmetal ions. Examples of chelator include ethylenediaminetetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), porphine, heme, ethylenediamine, or dimercaprol.
[0024] Flow cytometers are able to analyze several thousand cells every second, in "real time," and can actively separate and isolate cells having specified properties. A flow cytometer is similar to a microscope, except that, instead of producing an image of the cell, flow cytometry offers "high-throughput" (for a large number of cells) automated
quantification of set parameters. Adherent cells can be prepared for high throughput flow cytometry. Samples can be measured at a rate of up to 40 wells per minute. In addition, cells, such as BJ cells, can be seeded at a density of 5x10 cells per well with 96 well plates.
[0025] Recovery is the proportion of sorted cells of interest compared to the total number of cells of interest. In certain embodiments, percent of cells, such as adherent cells, recovered at the end can be 75% or more, 80% or more, 85% or more, 90% or more, or 95% or more.
[0026] In certain embodiments, the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry can be four hours or less, three hours or less, two hours or less, or one hour or less.
[0027] Conventional methods of flow cytometry often require removing media from cells, and lifting of the cells using solutions that often needs pipetting and may also require cell scraping. In the method here, the cells can be lifted without pipetting or scraping, the media do not have to be removed from wells, and the cell lifting solution can be added directly to the wells. In addition, the method here does not require washing or centrifugation step, and is less cumbersome and time consuming than the conventional protocol that requires washing or centrifugation step.
[0041] In addition, because the media does not have to be removed, the method here minimizes cells' time out of media, which lowers the baseline of apoptotic cells. The method here also minimizes cell trauma as neither scraping is required to lift cells nor harsh lifting solutions like trypsin are used. In addition, the method here can achieve effective separation. The percent of cells separated to single cells can be 75% or more, 80% or more, 85% or more, 90% or more, or 95% or more [0042] EXAMPLES
[0043] FIG. 1 illustrates the steps performed in one embodiment. As shown, cells are first plated in media. A control sample or drug sample can be added to the cells. The concentration of the drug sample and the time the cells are exposed to the drug sample can vary. The cell lifting solution can be added to the cells and incubated until the adherent cells lift from the culture container. A dye can be added to the cells prior to the cells being analyzed by flow cytometry. The protocol can be used to study the apoptosis induced after treatment with drug sample, for example, an apoptosis inducer.
[0044] In one method, five thousand cells were plated per well in 45μ1 of media in 96-well plate. The cells were shaken at 750 rpm with an Orbital shaker for 20 seconds and allowed to settle for 16-24 hrs in 5% C02 incubator at 37°C. A desired concentration of drug was added to cells in a volume of 5μ1 to make the final volume per well up to 50 μΐ. The cells and drug were mixed at 750 rpm with an Orbital shaker for 20 seconds and incubated again for desired period of time. Twelve microliters of 15mM EDTA pH 6.14 (upto 20mM can be added depending on the cell line) were added per well, mixed at 750 rpm with an Orbital shaker for 20 seconds and incubated at 37°C for 45 min to 1 hour (until cells lift). Fifteen microliters of media containing Ιμΐ APOPercentage dye was added to the cells and incubated for 15-20 min at 37°C. The cells were analyzed on flow cytometer setting a threshold for FSC-H of 80,000, cytometer speed at medium (2μ1/8εΰ), peristaltic pump speed at 23 rpm, shaking on 1800 rpm, gating on 2D plot of FSC vs SSC and a ID plot measuring FL2-H/FL3-H on the X axis. The HTFC system was used.
[0045] FIGS. 2, 3 and 4 showsthe results obtained using three different cell lines BJ, MCF-7 and HeLa, respectively, using the protocol shown in FIG. 1. The apoptotic cells were stained with the APOPercentage dye due to flipping of cell membrane, whereas non- apoptotic cells could not take up this dye due to a normal cell membrane.
[0046] BJ fibroblast cells were analyzed by flow cytometry on an Accuri C6 flow cytometer to determine the percentage of cells undergoing apoptosis (FIG. 2). Cells were seeded at a density of 5x10 cells per well in 96 well plate. Cells exposed to 2.5mM H202 for 30 minutes or 62 μΐ EDTA pH 6.14 for 15-30 min. added to cells after removing media were used as a positive control for apoptosis. Cells were lifted and stained with Ιμΐ APOPercentage dye. The cells were then analyzed by flow cytometry. As shown in FIG. 2A, untreated and treated cells were separated based on FL2-H and SSC-H profile. FIG. 2B includes a ID Histogram of untreated and treated cells showing the fluorescence measured in the FL2-H channel, where gates were applied to delineate non-apoptotic and apoptotic cells. FIG. 2C is a bar graph showing the percentage of non-apoptotic and apoptotic cells that was measured within the untreated or treated (positive control) population of cells. [0047] Untreated and treated MCF-7 cells were analyzed by flow cytometry on an Accuri C6 flow cytometer to determine the percentage of cells undergoing apoptosis (FIG. 3). Cells were seeded at a density of 5x10 cells per well in 96 well plate. Cells treated with 2.5mM H202 for 30 minutes or 62 μΐ EDTA pH 6.14 for 15-30 min. added to
cells after removing media were used as a positive control for apoptosis. The cells were lifted and stained with Ιμΐ APOPercentage dye. The cells were then analyzed by flow cytometry. Separation of untreated and treated cells based on FL2-H and SSC-H profile is shown in FIG. 3A. FIG. 3B shows a ID Histogram of untreated and treated cells showing the fluorescence measured in the FL2-H channel, where gates were applied to delineate non-apoptotic and apoptotic cells. FIG. 3C is a bar graph showing the percentage of non- apoptotic and apoptotic cells within the untreated or treated population of cells.
[0048] Untreated and treated HeLa cells were also analyzed by flow cytometry on an Accuri C6 flow cytometer to determine the percentage of cells undergoing apoptosis (FIG. 4). Cells were seeded at a density of 5x10 cells per well in 96 well plate. Cells treated with 2.5mM H202 for 30 minutes or 62 μΐ EDTA pH 6.14 for 15-30 min. added to cells after removing media wereused as a positive control for apoptosis. Cells were lifted and stained with Ιμΐ APOPercentage dye. The cells were then analyzed by flow cytometry. Separation of untreated and treated cells based on FL2-H and SSC-H profile is shown in FIG. 4A. FIG. 4B shows a ID Histogram of untreated and treated cells showing the fluorescence measured in the FL2-H channel, where gates were applied to delineate non-apoptotic and apoptotic cells. FIG. 4C is a bar graph showing the percentage of non- apoptotic and apoptotic cells within the untreated or treated population of cells.
[0049] The results showed that the untreated or non-apoptotic cells were unstained (i.e. did not take up dye), while cells undergoing apoptosis took up the dye. Generally, untreated cells can take up some dye as cells undergo apoptosis via a natural process, but this percentage in immortal cell line should not be as much as in cells with drug induced apoptosis. The results showed that, in the cell lines tested, the untreated cells had low numbers of positives (apoptotic cells), whereas most of the treated cells (apoptotic cells) were positively taking up the dye.
[0050] These results also showed that the protocol was stable in several cell lines tested. There was little overlap between untreated and treated cells in terms of positive staining. This confirmed that the method can have the capability to identify cells undergoing apoptosis from non-apoptotic cells. The results also confirmed that the treatment of cell lifting chemical was gentle and did not affect untreated cell membrane and also did not induce unwanted apoptosis in untreated cells.
[0051] Cell lines, such as HeLa and BJ fibroblasts, can have an elongated cell morphology. These cell lines can be more adherent and can also be more stable under assay conditions. On the other hand, the MCF-7 cells can be very sensitive and can have a tendency to respond to external factors with more sensitivity. Therefore, the percentage of cells taking up stain in untreated cells was little more using the MCF-7 cells as compared to other cell lines, but these limits were acceptable in flow cytometry.
[0052] Measuring apoptosis using APOPercentage Assay in adherent cells.
[0053] Cancer cells have the ability to avoid apoptosis, which thus presents an interesting event to quantify when determining the ability of drugs to induce apoptosis. Below the APOPercentage protocol with results is described for five cell lines (HeLa (Cervical cancer), MCF-7 (Breast Cancer), DU145 (Prostate Cancer), HT1080 (Colon Cancer), and BJ (Normal Fibroblasts). Apoptotic cells take up APOPercentage dye when membrane movement occurs and phosphatidylserine is exposed to the outer leaflet.
APOPercentage dye fluoresces in the FL-2 channel with a fluorescence of 590-600nm and can be measured by flow cytometry.
[0054] The following steps can be used to measure apoptosis using APOPercentage Assay in adherent cells. 5000 cells per well were plated in 45μ1 of media in 96-well plate, shaken at 750 rpm with an Orbital shaker for 20 seconds, and allowed to settle 16-24 hours (h). Desired concentration of drug was added to cells in a volume of 5μ1 to make the final volume per well up to 50 μΐ, was shaken at 750 rpm with an Orbital shaker for 20 seconds, and was then incubated for desired period of time. 12 μΐ of 15 mM EDTA pH 6.14 per well was added (upto 20mM can be added depending on the cell line). Shake at 750 rpm with an Orbital shaker for 20 seconds and incubate at 37°C for 15 minutes (min) to 1 h (until cells lift). Add 15μ1 of serum free media containing Ιμΐ APOPercentage dye and incubate for 15-20 min at 37°C. Analyze on flow cytometer setting a threshold for FSC-H of 80 000, cytometer speed at medium (2 μΐ/sec), peristaltic pump speed at 23 rpm, gating on 2D plot of FSC vs SSC and a ID plot measuring FL2-H/FL3-H on the X axis. 2.5 mM Η202 is used as a positive control.
[0055] FIGS. 5A-C and Table 1 show results of APOPercentage assay in 96-well plate on Accuri C6 HTFC System ( Intellicyt).
[0056] FIGS. 5A-C show that HeLa Cells untreated (blue) or treated (red) were analyzed by flow cytometry on an Accuri C6 flow cytometer to determine the percentage
of cells undergoing apoptosis. Cells were seeded at a density of 5x10 cells per well in a 96-well plate. Following day, cells were treated with 2.5 mM Η202 for 30 min. or 62 μΐ EDTA pH 6.14 for 15-30 min. added to cells after removing media as a positive control for apoptosis for 15-30 min. Cells were lifted with EDTA and stained with Ιμΐ
APOPercentage and analyzed by flow cytometry. Separation of untreated (blue) and treated (red) cells based on FL2-H and SSC-H profile (FIG. 5A). ID Histogram of untreated (blue) and treated (red) cells measuring fluorescence in the FL2-H channel and applying gates to delineate Non-apoptotic (blue) and Apoptotic (red) cells (FIG. 5B). Bar graph showing the percentage of non-apoptotic and apoptotic cells within the untreated or treated (positive control) population of cells (FIG. 5C).
[0057] Table 1 shows different aspects of method standardized using various cell lines. 'Stability of cells in EDTA' refers to the time limit until the percentage of stained cells remain <10% in negative control.
[0058] Table 1
[0059] FIG. 6 and Table 2 show results of APOPercentage assay in 96-well plate on BD LSRFortessa HTS (BD Biosciences).
[0060] In FIG. 6, MCF-7 Cells untreated (blue, left) or treated (red, right) were analyzed by flow cytometry on a BD LSRFortessa HTS flow cytometer to determine the percentage of cells undergoing apoptosis. Data was analyzed using FlowJo version 7.6.5 software. Cells were seeded at a density of 5x10 cells per well in a 96-well plate.
Following day, cells were treated with 2.5 mM H202 for 30 min or 62 μΐ EDTA pH 6.14 after removing media for 20-30 min. as a positive control for apoptosis. Cells were lifted with EDTA and stained with Ιμΐ APOPercentage and analyzed by flow cytometry. ID
Histogram of untreated (blue) and treated (red) cells measuring fluorescence in the PE-A channel and applying gates to delineate Non-apoptotic (blue) and Apoptotic (red) cells.
[0061] Table 2 shows APOPercentage assay results for three cell lines tested on BD LSRFortessa HTS. Table represents data for three cell lines displaying percentage cells stained positive with APOPercentage dye in 'Untreated' (-ve) and 'Treated' (+ve) controls along with S.D.
[0062] Table 2
[0063] Determining Mitochondrial Membrane Potential (MMP) by Flow Cytometry in adherent cells
[0064] A common feature of cells undergoing early stage apoptosis is disruption of mitochondria. MMP is a reflection of the permeability of the mitochondria membrane as it consists of an outer and inner membrane, which maintains a gradient of H+ ions at the inner membrane space. These H+ ions are used in the production of ATP, which serves as an energy source required for enzymatic reactions to take place and to balance energy homeostasis within the cell. Cells undergoing apoptosis often experience a decrease in ATP supply as a result of MMP disruption. Furthermore, disruption of MMP leads to the release of proapoptotic factors, such as cytochrome c, from the mitochondria into the cytosol, thus driving cells towards apoptosis. JC-1 is a membrane permeable dye with interesting fluorescence spectrum depending on the state of the dye. In healthy cells, the MMP is not disrupted and JC-1 accumulates in the mitochondria as it is attracted to the high electrochemical-gradient maintained within the inner membrane. When JC-1 accumulates it forms J aggregates, which have a fluorescence emission at 580-590 nm thus fluorescing red. In cells undergoing apoptosis, where MMP has been disrupted, JC-1 cannot aggregate due to loss of the gradient within the mitochondria and therefore remains in a monomeric state resulting in a fluorescence emission of 530 nm (green fluorescence). This unique characteristic allows distinguishing apoptotic from non- apoptotic cells at early stages of cell death when MMP is lost.
[0065] The following can be the steps used to determining MMP by Flow Cytometry in adherent cells. 5000 cells per well were plated in 45μ1 of media in 96-well plate, shaken at 750 rpm with an Orbital shaker for 20 seconds, and allowed to settle 16-24 hours (h). Desired concentration of drug was added to cells in a volume of 5μ1 to make the final volume per well up to 50 μΐ, was shaken at 750 rpm with an Orbital shaker for 20 seconds, and was then incubated for desired period of time. 12 μΐ of 15 mM EDTA pH 6.14 (upto 20mM can be used depending on cell line) per well was added. Shake at 750 rpm with an Orbital shaker for 20 seconds and incubate at 37°C for 15 minutes (min) to 1 h (until cells lift). Add 15 μΐ of serum free media containing JC-1 dye so that the final concentration is 2 μΜ in a total volume of 77 μΐ and incubate for 1-2 h at 37°C. Analyze on flow cytometer setting a threshold for FSC-H of 80 000, cytometer speed at medium (2 μΐ/sec), peristaltic pump speed at 23 rpm, gating on 2D plot of FSC vs SSC, performing a quadrant gate in a 2D plot of FL2-H vs FL-1H applying compensation FL-2H minus FL- 1H to separate populations and a ID plot measuring FL2-H on the X axis. 100 mM H202 can be used as a positive control.
[0066] FIGS. 7A-B and Table 3 show results of MMP assay in 96-well plate on Accuri C6 HTFC System ( Intellicyt).
[0067] In FIGS. 7A-B, DU145 Cells unstained (blue), untreated (red) or treated (green) were analyzed by flow cytometry on an Accuri C6 to determine the percentage of cells with disrupted MMP. Cells were seeded at a density of 5x10 cells per well in 96- well plate. Following day media was removed from cells and replaced with 50 μΐ EDTA as a positive control for MMP disruption for 60 min. Cells were lifted with EDTA and stained with a final concentration of 2 μΜ JC-1 dye and analyzed by flow cytometry. Separation of unstained (blue), untreated (red) and treated (green) cells based on FL2-H and FL-l-H profile (A). ID Histogram of unstained (blue), untreated (red) and treated (green) cells measuring fluorescence in the FL2-H channel (B).
[0068] Table 3 shows different aspects of method standardized using various cell lines. 'Stability of cells in EDTA' refers to the time limit until the percentage of cells having JC-1 green remain <10% in negative control. [0069] Table 3
Cell Line Time to lift with EI>TA Time to stain Stability in JC-l dye Percent ceils Percent cells (stability of c lis iit with JC-l after staining lias ing JC-l green having JC-l EDTA) ti untreated greeii in treated negative control positive control
DU145 20-30miu 60mm 60 m.+ 10 90
(stable up 2k)
HeLa 30-45mm δ ηιϊη i2l>min 90
(stable up to 90 Him)
MCF-7 15-20min 6θΗΐίη 12¾iiia
[0070] FIG. 8 and Table 4 show MMP assay in 96-well plate on BD LSRFortessa
HTS (BD Biosciences).
[0071] In FIG. 8, DU145 and MCF-7 Cells were analyzed by flow cytometry on a BD LSRFortessa HTS to determine the level of MMP in cells. Data was analyzed using
FlowJo version 7.6.5 software. Cells were seeded at a density of 5x10 cells per well in a 96-well plate, the following day cells were left untreated (red) or treated with 100 mM
H2O2 as a positive control (blue) for MMP disruption. DU145 cells were stained with a final concentration of 2 μΜ JC-l dye (representative image). Cells were lifted with
EDTA and analyzed by flow cytometry.
[0072] Table 4 shows MMP assay results for two cell lines tested on BD LSRFortessa HTS. Table represents median of the peaks of MMP in untreated (-ve) and treated (+ve) cells for two different cell lines.
[0073] Table 4
[0074] In above experiment, JC-l dye is accumulated in cells having intact MMP, therefore untreated negative controls show more accumulation of dye (as represented by median values in Table 4).
[0075] MMP can be measured in adherent cells in 384-well plate format. The
following steps can be used. 3000 cells per well were plated in 15 μΐ of media in 384-well plate, centrifuged at 1000 rpm for 30 seconds, and shaken at 1500 rpm with an Orbital shaker for 20 seconds and allowed to settle 16-24 hours (h). Desired concentration of drug was added to cells in a volume of 3 μΐ to make the final volume per well up to 20 μΐ. Incubate with drug for desired period of time. Centrifuge at 1000 rpm for 30 seconds and
shake at 2000 rpm with an Orbital shaker for 20 seconds. Stain cells by adding 2 μΐ of JC- 1 to a final concentration of 2 μΜ in a final volume of 20 μΐ. Centrifuge at 1000 rpm for 30 seconds and shake at 2000 rpm with an Orbital shaker for 20 seconds and incubate with stain for 30 min at 37 °C. Add 5 μΐ of 15 mM EDTA pH 6.14 per well (upto 20mM can be used depending on cell line), shake at 2000 rpm with an Orbital shaker for 20 seconds and incubate at 37 °C for 55 minutes (min) to 1 h (until cells lift). Analyze on flow cytometer. The results indicate that the ratios of negative and positive controls are similar to that obtained for 96- well plate format. The assay is stable in 384- well plate thus providing platform for high throughput testing of large number of samples. [0076] Measuring Reactive Oxygen Species (ROS) by Flow Cytometry in adherent cells.
[0077] Reactive oxygen species (ROS) are oxygen species with an extra electron charge e.g. O 2-" and OH". These reactive molecules are produced in cells as by-products of cellular pathways e.g. oxidative phosphorylation and play a role in cell signaling pathways. A balance of these species is required in the cell as excessive ROS can cause adverse effects and can lead to diseases like cancer, atherosclerosis and certain neurodegenerative diseases. ROS is kept in check by antioxidants like Glutathione peroxidase, catalase and superoxide dismutase (SOD), which serve to protect against ROS stress. Excessive ROS production can lead to protein unfolding, disruption of enzyme activity and also DNA damage as the available electrons in ROS can
attack/reduce positively charged groups within proteins and DNA. Measuring ROS is therefore important as it gives an indication of the oxidative stress level within the cell, which might play a role in necrosis or apoptosis. 2', 7' -dichlorofluorescein diacetate (DCFDA) is a cell permeable fluorescent molecule, which is deacetylated by cellular esterases and becomes free to react with ROS, thus forming stable 2', 7' - dichlorofluorescin (DCF). DCF is stable and highly fluorescent and can be measured by flow cytometry with excitation of 495 nm and emission of 530 nm.
[0078] The following steps can be used to measure Reactive Oxygen Species (ROS) by Flow Cytometry in adherent cells. Plate 5000 cells per well in 45μ1 of media in 96- well plate. Shake at 750 rpm with an Orbital shaker for 20 seconds and allow cells to settle 16-24 hours (h). Add desired concentration of drug to cells in a volume of 3 μΐ to make the final volume per well up to 48 μΐ. Add 2 μΐ DCFDA so that the final concentration is 10 μΜ in a total volume of 50 μΐ. Shake at 750 rpm with an Orbital
shaker for 20 seconds and incubate at 37°C and assay from 1 h onwards. Add 12 μΐ 15 mM EDTA pH 6.14 per well (upto 20mM can be used depending on cell line), shake at 750 rpm with an Orbital shaker for 20 seconds and incubate at 37°C for 15 min to 1 h (until cells lift). Add 15 μΐ of serum free media and incubate for 5-10 min. Analyze on flow cytometer setting a threshold for FSC-H of 80 000, cytometer speed at medium (2 μΐ/sec), peristaltic pump speed at 23 rpm, gating on 2D plot of FSC vs SSC and a ID plot measuring FL1-H on the X axis. 2-10 mM Η202 is used as a positive control.
[0079] FIGS. 9A-B and Table 5 show results of ROS assay in 96-well plate on Accuri C6 HTFC System ( Intellicyt). [0080] In FIG. 9, HeLa and MCF-7 Cells were analyzed by flow cytometry on an Accuri C6 to determine the level of ROS in cells. Cells were seeded at a density of 5x10 cells per well in a 96-well plate, the following day cells were treated with 10 mM H202 as a positive control for ROS and test compounds. HeLa cells were stained with a final concentration of 10 μΜ DCFDA dye immediately after adding H202 (A). After incubation cells were lifted with EDTA and analyzed by flow cytometry. Separation of untreated (yellow) and treated (purple) cells based on FL-l-H profile (A). MCF-7 cells were treated with Plumbagin and its derivative Crotonate Plumbagin for 1 h (B). A final 10 μΜ DCFDA was added simultaneously with Plumbagin and its derivative to cells. Following incubation with drug cells were lifted with EDTA and analyzed by flow cytometry.
[0081] Table 5 shows different aspects of method standardized using various cell lines. 'Stability of cells in EDTA' refers to the time limit until the percentage of cells stained with DCFDA remain <10% in negative control.
[0082] Table 5
[0083] FIGS. 10A-B and Table 6 show results of ROS assay in 96-well plate on BD LSRFortessa HTS (BD Biosciences)
[0084] In FIGS. 10A-B, MCF-7 and HeLa Cells were analyzed by flow cytometry on a BD LSRFortessa HTS to determine the level of ROS in cells. Data was analyzed using FlowJo version 7.6.5 software. Cells were seeded at a density of 5x10 cells per well in a 96-well plate, the following day cells were left untreated (blue peak) or treated with 10 mM H2O2 as a positive control (red peak) for ROS. MCF-7 and HeLa cells were stained with a final concentration of 10 μΜ DCFDA dye immediately after adding H202 (A and B). Cells were lifted with EDTA and analyzed by flow cytometry. [0085] Table 6 shows ROS assay results for three cell lines tested on BD
LSRFortessa HTS. Table 6 represents median of the peaks of ROS generation in untreated (-ve) and treated (+ve) cells for three different cell lines.
[0086] Table 6
[0087] ROS can be measured in adherent cells in 384- well plate format. The following can be the steps. Plate 3000 cells per well in 15 μΐ of media in 384-well plate. Centrifuge at 1000 rpm for 30 seconds and shake at 1500 rpm with an Orbital shaker for 20 seconds and allow cells to settle 16-24 hours (h). Add desired concentration of drug to cells in a volume of 3 μΐ to make the final volume per well up to 20 μΐ. Incubate with drug for desired period of time. Centrifuge at 1000 rpm for 30 seconds and shake at 2000 rpm with an Orbital shaker for 20 seconds. Stain cells by adding 2 μΐ of DCFDA to a final concentration of 10 in a final volume of 20 μΐ. Centrifuge at 1000 rpm for 30 seconds and shake at 2000 rpm with an Orbital shaker for 20 seconds and incubate with stain for 30 min at 37 °C. Add 5 μΐ of 15 mM EDTA pH 6.14 per well (upto 20 mM can be used depending on cell line), shake at 2000 rpm with an Orbital shaker for 20 seconds and incubate at 37 °C for 45 minutes (min) to 1 h (until cells lift). Analyze on flow cytometer.
[0088] The results indicate that the ratios of negative and positive controls are similar to that obtained for 96- well plate format. The assay is stable in 384- well plate thus providing platform for high throughput testing of large number of samples.
[0089] Measuring Autophagy by Flow Cytometry in adherent cells [0090] Autophagy is a naturally occurring cellular process, which recycles proteins or amino acids, provides energy during starvation or under excessive activity, and is also recognized as another form of apoptosis. Similar to apoptosis, which involves regulators and initiators, autophagy is a controlled process. Proteins are degraded by the lysosomal pathway or recycled by endosomes. Under conditions involving stress or low levels of nutrients, autophagosomes, double membrane structures consisting of early autophagic proteins e.g. Beclin and ATG5, begin forming. These then fuse to lysosomes to form what is known as the autolysosome or autophagosome. Autophagosomes degrade proteins, damaged organelle like mitochondria and by so doing provides substrates for ATP production. When excessive autophagy (termed macrophagy/ mitophagy) occurs, cells undergo apoptosis. Uncontrolled autophagy has been linked to diseases like cancer, inflammatory bowel disease and neurodegenerative disorders. Since autophagy can act as a survival pathway for cells, but its excessive activation can lead to cell death. Therefore, it is another marker to measure cell stress and apoptosis when assessing the effects of unknown drugs. Monodansylcadaverine (MDC) is a fluorescent dye with excitation 335 nm and emission 512 nm. It binds selectively to autophagosomes and can be detected by flow cytometry.
[0091] The following steps can be used. 5000 cells per well were plated in 45μ1 of media in 96-well plate, shaken at 750 rpm with an Orbital shaker for 20 seconds, and allowed to settle 16-24 hours (h). Desired concentration of drug was added to cells in a volume of 5μ1 to make the final volume per well up to 50 μΐ, was shaken at 750 rpm with an Orbital shaker for 20 seconds, and was then incubated for desired period of time. 12 μΐ of 15 mM EDTA pH 6.14 per well (upto 20 mM can be used depending on cell line) was added. Shake at 750 rpm with an Orbital shaker for 20 seconds and incubate at 37°C for 15 minutes (min) to 1 h (until cells lift). Add 15 μΐ of serum free media containing MDC dye so that the final concentration is 50 μΜ in a total volume of 77 μΐ and incubate for 15 min at 37°C. Analyze on flow cytometer setting a threshold for FSC-H of 80 000, cytometer speed at medium (2 μΐ/sec), peristaltic pump speed at 23 rpm, gating on 2D
plot of FSC vs SSC and a ID plot measuring FLl-H on the X axis. 10 μΜ Z36 an inducer of autophagy is used as a positive control.
[0092] Table 7 shows the results of Autophagy assay. Table 7 shows different aspects of method standardized using various cell lines. 'Stability of cells in EDTA' refers to the time limit until the percentage of cells stained with MDC remain <10% in negative control.
[0093] Table 7
[0094] Comparison of cell number loss using conventional method and "Our method" [0095] The conventional method can be compared with "Our method" for estimating the cell numbers in samples undergoing flow cytometry analysis. "Our method" is an example of the method comprising adding a cell lifting solution to a media including a sample of adherent cells, and incubating the sample of adherent cells with the cell lifting solution. [0096] Conventional method in 96-well format includes plating 3-5xl03 cells in 96- well plate, treating with drug, removing media and rinse once with trypsin, lifting cells with trypsin (5-10 minutes), adding media to neutralize trypsin, pelleting cells by centrigugation (5 minutes), removing supernatant, washing twice with plate washer, pelleting cells by centrifugation (5 minutes), resuspending cell pellets in staining solutions (15 minutes), pelleting cells by centrifugation (5 minutes), removing
supernatant and resuspending cell pellets, and analyzing on flow cytometer. Total time in practice for conventional method takes more than one hour.
[0097] "Our method" includes plating 3-5xl03 cells in 96-well plate, treating with drug, adding our cell lifting solution (15-20 mM EDTA Ph 6.14) (15 minutes), adding stain (15 minutes), and analyzing on flow cytometer. Total time in practice for "our method" is 35-40 minutes. Conventional method has several wash steps, which leads to cell loss in the sample. On the contrary, "Our method" does not use any wash steps.
[0098] The samples using DU145 cells and HeLa cells were processed in 96-well plates using conventional method and 'Our method' . The cell loss with each consecutive wash step using conventional protocol is shown in FIGS. 11A-B. Equal amount of final volume having suspended cells was used for flow cytometry analysis. The protocols, as shown below, were performed using two cell lines. FIGS. 11A-B shows the percentages of cells after various wash steps using conventional protocol and "Our method". FIG. 11A shows results for DU145 cells, and FIG. 11B shows results for HeLa cells.
[0099] The described method works equally well when performed by a non-biologist user. A kit can be created with components such as buffer and APOPercentage dye, and instructions can be prepared. The method is simple and efficient that any non- skilled person in biological methods can also perform the experiments with high accuracy.
[00100] The described method has several advantages over conventional method. As shown above, conventional method can cause loss of more than 80% cells in 96-well format after two washes while 'Our method' retains the cells in samples as no washing is required. In "our method," cells are grown, lifted and stained in the same well, which minimizes cell loss; there was direct staining, where cells are stained in the presence of cell lifting agent and media; no-media removal is needed, because the cell lifting solution is added directly to media; no washing of cells by using multiple centrifugation steps required; sample preparation is faster; cells are stable for longer time in the buffer, and so on. "Our method" makes High Throughput screening of adherent cells a reality.
[00101] The various embodiments described above are provided by way of illustration only and should not be construed to limit the claimed invention. Those skilled in the art will readily recognize various modifications and changes that may be made to the claimed invention without following the example embodiments and applications illustrated and described herein, and without departing from the true spirit and scope of the claimed invention, which is set forth in the following claims.
Claims
1. A method for detaching adherent cells, comprising:
adding a cell lifting solution to a media including a sample of adherent cells; and incubating the sample of adherent cells with the cell lifting solution.
2. The method of claim 2, wherein the sample of adherent cells includes HeLa cells, DU145 cells, HT1080 cells, BT20 cells, MCF-7 cells or BJ fibroblasts.
3. The method of claim 1, wherein the sample of adherent cells is incubated with the cell lifting solution for five minutes or more.
4. The method of claim 3, wherein the sample of adherent cells is incubated with the cell lifting solution for fifteen minutes or more.
5. The method of claim 4, wherein the sample of adherent cells is incubated with the cell lifting solution for thirty minutes or more.
6. The method of claim 1, wherein the cell lifting solution includes a metal ion chelator.
7. The method of claim 6, wherein the metal ion chelator is EDTA.
8. The method of claim 1, wherein the cell lifting solution is free of enzyme.
9. A method for detaching adherent cells for flow cytometry, comprising:
adding a cell lifting solution to a media including a sample of adherent cells; and incubating the sample of adherent cells with the cell lifting solution; and analyzing the sample of adherent cells by flow cytometry.
10. The method of claim 9, further comprising adding an indicator of apoptosis to the sample of adherent cells.
11. The method of claim 10, wherein the indicator of apoptosis, ROS, MMP and autophagy is a dye, a fluorophore or an antibody.
12. The method of claim 10, further comprising adding a stimulus to the media.
13. The method of claim 12, wherein the stimulus is a drug.
14. The method of claim 9, wherein the adherent cells are not washed with a washing solution between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry.
15. The method of claim 9, wherein the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry is four hours or less.
16. The method of claim 9, wherein the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry is three hours or less.
17. The method of claim 9, wherein the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry is two hours or less.
18. The method of claim 9, wherein the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry is one hour or less.
19. The method of claim 9, wherein the time period between adding the cell lifting solution to the media and analyzing the adherent cells by flow cytometry is 15-30 minutes or less.
20. The method of claim 12, wherein the stimulus is added to the media prior to adding the cell lifting solution to the media.
21. The method of claim 9, wherein the cell lifting solution includes a metal ion chelator.
22 The method of claim 9, wherein the metal ion chelator is EDTA.
23. A method of collecting adherent cells, comprising:
plating a first sample of adherent cells in media on a cell plate;
plating a second sample of adherent cells in media on a cell plate, wherein the second sample of adherent cells includes a second number of adherent cells;
adding a control buffer to the media of the first sample of adherent cells;
adding a stimulus to the media of the second sample of adherent cells;
adding cell lifting solution to the media of the first sample of adherent cells and to the media of the second sample of adherent cells, wherein the first sample includes a first number of adherent cells at the time the cell lifting solution is added to the media and the second sample includes a second number of adherent cells at the time the cell lifting solution is added to the media;
incubating the first and second samples of adherent cells, thereby detaching the first and second samples of adherent cells from the cell plate;
collecting the first sample of adherent cells, wherein the number of adherent cells collected from the first sample is equal to 75% or more of the number of adherent cells in the first sample when the cell lifting solution was added; and
collecting the second sample of adherent cells, wherein the number of adherent cells collected from the second sample is equal to 75% or more of the number of adherent cells in the second sample when the cell lifting solution was added.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/764,357 US20150368620A1 (en) | 2013-01-30 | 2014-01-29 | Method of detaching adherent cells for flow cytometry |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361758527P | 2013-01-30 | 2013-01-30 | |
US61/758,527 | 2013-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014132142A2 true WO2014132142A2 (en) | 2014-09-04 |
WO2014132142A3 WO2014132142A3 (en) | 2014-12-04 |
Family
ID=51136517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2014/001133 WO2014132142A2 (en) | 2013-01-30 | 2014-01-29 | Method of detaching adherent cells for flow cytometry |
Country Status (2)
Country | Link |
---|---|
US (1) | US20150368620A1 (en) |
WO (1) | WO2014132142A2 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1404180A4 (en) * | 2001-06-04 | 2004-10-20 | Cytokine Pharmasciences Inc | Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
FR2831554B1 (en) * | 2001-10-30 | 2004-08-20 | Centre Nat Rech Scient | METHOD FOR ENRICHMENT OF KERATINOCYTAIC STEM CELLS |
US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
US20040203142A1 (en) * | 2003-04-14 | 2004-10-14 | Reliance Life Sciences Pvt. Ltd. | Growth of neural precursor cells using umbilical cord blood serum and a process for the preparation thereof for therapeutic purposes |
WO2008043153A1 (en) * | 2006-10-11 | 2008-04-17 | Medvet Science Pty. Ltd. | A method of diagnosis and agents useful for same |
WO2010088735A1 (en) * | 2009-02-05 | 2010-08-12 | Regenertech Pty Ltd | Method of producing progenitor cells from differentiated cells |
-
2014
- 2014-01-29 WO PCT/IB2014/001133 patent/WO2014132142A2/en active Application Filing
- 2014-01-29 US US14/764,357 patent/US20150368620A1/en not_active Abandoned
Non-Patent Citations (5)
Title |
---|
BERTHO AL ET AL.: "Flow cytometry in the study of cell death", MEM INST OSWALDO CRUZ, vol. 95, 2000, pages 429 - 433 |
BLACK CB ET AL.: "Cell-based screening using high-throughput flow cytometry", ASSAY DRUG DEV TECHNOL, vol. 9, 2011, pages 13 - 20 |
DENECKER G ET AL.: "Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential", FEBS LETT, vol. 465, 2000, pages 47 - 52 |
WLODKOWIC D ET AL.: "Cytometry of apoptosis. Historical perspective and new advances", EXP ONCO1, vol. 34, 2012, pages 255 - 262 |
YIVGI-OHANA N ET AL.: "Utilizing mitochondrial events as biomarkers for imaging apoptosis", CELL DEATH DIS, vol. 2, 2011, pages E166 |
Also Published As
Publication number | Publication date |
---|---|
US20150368620A1 (en) | 2015-12-24 |
WO2014132142A3 (en) | 2014-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2534463B1 (en) | Method for analysis of cellular dna content | |
Kang et al. | Embryonic and induced pluripotent stem cell staining and sorting with the live-cell fluorescence imaging probe CDy1 | |
US10000793B2 (en) | Method for enumeration of mammalian cell micronuclei, while distinguishing chromatin of dead and dying cells | |
Van den Hurk et al. | Patch-seq protocol to analyze the electrophysiology, morphology and transcriptome of whole single neurons derived from human pluripotent stem cells | |
Pargett et al. | Single-cell imaging of ERK signaling using fluorescent biosensors | |
Czupalla et al. | Collagenase-based single cell isolation of primary murine brain endothelial cells using flow cytometry | |
KR20160137697A (en) | Methods for Detecting, Identifying or Counting Microorganism and Systems Using Thereof | |
Morrison et al. | Quantitative single cell gene expression profiling in the avian embryo | |
Shibuta et al. | Imaging cell picker: A morphology-based automated cell separation system on a photodegradable hydrogel culture platform | |
Nijssen et al. | Axon-seq for in depth analysis of the RNA content of neuronal processes | |
Ranade et al. | High content imaging and analysis enable quantitative in situ assessment of CYP3A4 using cryopreserved differentiated HepaRG cells | |
Dias et al. | Using fluorescence for improvement of the quantitative analysis of micronucleus in cell culture | |
US20150368620A1 (en) | Method of detaching adherent cells for flow cytometry | |
US20190345536A1 (en) | Detection method for chromosomal abnormalities and method for evaluating inducibility | |
Zhang et al. | Stable isotope labeling by amino acids in cultured primary neurons | |
Mullooly et al. | A multi-parametric high throughput assay for detecting beta-cell proliferation in dispersed primary islets | |
CN113774147A (en) | Application of m6A RNA methylation motif in preparation of cell senescence diagnostic kit | |
Otto | Fluorimetric DNA assay of cell number | |
Hailer et al. | Isolation of human cutaneous immune cells for single-cell RNA sequencing | |
Fernandez-Gutierrez et al. | High-throughput screening model to quantify re-epithelialization kinetics | |
Buzgariu et al. | Combining BrdU-labeling to detection of neuronal markers to monitor adult neurogenesis in hydra | |
Buzgariu et al. | Studying Stem Cell Biology in Intact and Whole-Body Regenerating Hydra by Flow Cytometry | |
JP2007526743A (en) | A method for assessing the invasive potential of cells using chromatin analysis | |
CN114459857B (en) | Pretreatment method for maintaining animal sperm motility and animal sperm apoptosis determination | |
CN104160017B (en) | Method for determining teratogenic risk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14736438 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14764357 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14736438 Country of ref document: EP Kind code of ref document: A2 |